Praveen Tipirneni

Praveen Tipirneni is the CEO of Morphic Therapeutic, a biopharmaceutical company pioneering the development of oral integrin therapies. Since joining Morphic in 2015, Praveen has led the company through significant milestones, including a strategic IPO and a recent acquisition by Eli Lilly valued at approximately $3.2 billion. His leadership has been instrumental in advancing Morphic’s alpha 4 beta 7 program and other innovative treatments for autoimmune diseases. Before Morphic, Praveen served as Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals, where he played a key role in the company’s growth and eventual acquisition by Merck. His career also includes strategic roles at Sun Microsystems, Covad Communications, and Deltagen. Praveen holds an MD from McGill University and an MBA in Healthcare Finance from The Wharton School. He completed his undergraduate studies in Mechanical Engineering at MIT. In addition to his professional achievements, Praveen is a former 1st Lieutenant in the U.S. Army and is recognized for his expertise in biochemistry and biopharmaceuticals. Praveen frequently shares insights on strategic leadership, the biotech landscape, and the importance of building strong teams through his LinkedIn posts and other platforms.